CDR Life Sciences

@CDRLifeSciences

Inspired, results-focused communications & IR advice & execution for life sciences companies making a difference. Tweets by Life Sciences team

London
Vrijeme pridruživanja: veljača 2014.

Tweetovi

Blokirali ste korisnika/cu @CDRLifeSciences

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @CDRLifeSciences

  1. proslijedio/la je Tweet
    3. velj
    Poništi
  2. proslijedio/la je Tweet
    4. velj

    Our COO, Simon Baeriswyl, is talking to @ScripLucie at Congress about our Pharma partnerships, in particular our licensing and co-development deal with Takeda

    Poništi
  3. proslijedio/la je Tweet
    31. sij

    are attending the BIO CEO & Investor Conference from 10-11 February 2020 in New York. will be presenting our needle-free solid dose technology on Monday 10th February .45pm in the Wilder Room.

    Poništi
  4. proslijedio/la je Tweet
    4. velj

    is excited to be nominated for a ViE Award in the Best New Vaccine Technology/Platform (category #7). Please vote for us here to recognise the potential of our ImplaVax® vaccination technology platform

    Poništi
  5. proslijedio/la je Tweet
    30. sij

    New Funds Extend Chi-Med’s Runway But HK Listing Still Planned

    Poništi
  6. proslijedio/la je Tweet
    28. sij
    Poništi
  7. proslijedio/la je Tweet
    30. sij

    We start 2020 with the first novel drug designed by entering human clinical trials. By the end of this new decade, we expect all drugs will be developed using AI. Read ’s piece about this critical milestone

    Poništi
  8. proslijedio/la je Tweet
    24. sij

    Cardiff University and Ervaxx turn to the dark side to fight cancer is looking to and their Dark Antigens to build on research which could lead to a universal treatment.

    Poništi
  9. proslijedio/la je Tweet
    27. sij

    "Treatment with [TYK2/JAK1 inhibitor] PF-06700841 rapidly improves disease activity in patients with chronic plaque psoriasis by inhibiting pro-inflammatory cytokines that require TYK2 and JAK1 for signal transduction"

    Poništi
  10. 24. sij

    Acacia Pharma has been awarded BEL Small Company of the Year 2019 by at its New Year Ceremony last night

    Poništi
  11. proslijedio/la je Tweet
    24. sij

    Thrilled today to announce our collaboration with to develop novel and immunotheraies targeting . We will also build on exciting new research in identifying as a target for novel .

    Poništi
  12. proslijedio/la je Tweet
    23. sij

    Congratulations to Jackie Grant, Principal in our Boston, MA office, who has been elected to the Board of Directors of Center

    Poništi
  13. 22. sij

    Oculis announces upcoming presentation of Phase 2 data of OCS-01, its investigational topical back-of-the-eye treatment, in patients with () on 8 February at Angiogenesis, Exudation, and Degeneration 2020

    Poništi
  14. proslijedio/la je Tweet
    17. sij

    Antabio’s CF program funded by CARB-X highlighted in Forbes

    Poništi
  15. proslijedio/la je Tweet
    21. sij

    Early stop of SANET-p Phase III after +ve interim analysis. Likely China NDA filing (2nd indication) in 2020 & potentially unique position as effective therapy across the NET () spectrum. Read more on at:

    Poništi
  16. proslijedio/la je Tweet
    21. sij

    Key message from Albert Baehny, Chairman and CEO ad interim, on our results:

    Poništi
  17. proslijedio/la je Tweet
    21. sij

    Immuno-oncology (including Sareum's SDC-1802): All you wanted to know but were too afraid to ask via

    Poništi
  18. proslijedio/la je Tweet
    21. sij

    Drug would be Chi-Med's first fully independent launch in More Surufatinib Cheer For Chi-Med As Second NET Trial Stopped Early

    Poništi
  19. proslijedio/la je Tweet
    21. sij

    More Surufatinib Cheer For Chi-Med As Second NET Trial Stopped Early

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·